166 related articles for article (PubMed ID: 30061130)
21. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
[TBL] [Abstract][Full Text] [Related]
22. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
23. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
24. Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation.
Alhefzi M; Aycart MA; Bueno EM; Kueckelhaus M; Fischer S; Snook RJ; Sharfuddin AA; Hadad I; Malla P; Amato AA; Pomahac B; Marty FM
Transpl Infect Dis; 2016 Apr; 18(2):288-92. PubMed ID: 26910286
[TBL] [Abstract][Full Text] [Related]
25. Valganciclovir treatment of primary cytomegalovirus pneumonitis in an immunocompetent adult.
Snape SE; Venkatesan P
BMJ Case Rep; 2011 Mar; 2011():. PubMed ID: 22707605
[TBL] [Abstract][Full Text] [Related]
26. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
Cvetković RS; Wellington K
Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
[TBL] [Abstract][Full Text] [Related]
28. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
29. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
Liu KY; Wang Y; Han MZ; Huang H; Chen H; Liu QF; Wang JM; Liu T; Song YP; Ma J; Wu DP; Zou P; Huang XJ
Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
[TBL] [Abstract][Full Text] [Related]
30. Congenital Cytomegalovirus.
Mestas E
Adv Neonatal Care; 2016 Feb; 16(1):60-5. PubMed ID: 26752783
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus viremia in lung transplantation during and after prophylaxis.
Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P
Transpl Infect Dis; 2019 Jun; 21(3):e13069. PubMed ID: 30884067
[TBL] [Abstract][Full Text] [Related]
32. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
33. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Am J Transplant; 2010 Jan; 10(1):157-61. PubMed ID: 19889123
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
37. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.
Zamora MR; Nicolls MR; Hodges TN; Marquesen J; Astor T; Grazia T; Weill D
Am J Transplant; 2004 Oct; 4(10):1635-42. PubMed ID: 15367218
[TBL] [Abstract][Full Text] [Related]
38. Incidence and risk factors for the development of cytomegalovirus viremia in a steroid sparing liver transplant center.
Viehl E; Lichvar A; Chan C; Choi D
Transpl Infect Dis; 2022 Aug; 24(4):e13867. PubMed ID: 35604549
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus-induced hemorrhagic cystitis in AIDS patient treated successfully with valganciclovir.
Studemeister A
AIDS; 2002 Jul; 16(10):1437-8. PubMed ID: 12131229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
